SCI & TECH● LOW2h ago · Sep 3, 2026, 5:55 AM
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Seeking Alpha Tech · global
Ultragenyx shares dropped following the failure of a Phase 3 trial for its Angelman syndrome drug. This outcome is a significant setback for the company's pharmaceutical development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH29m agoWhere Does AI Escalation Come From? We Don’t Know. We Should Find Out.War on the RocksSCI & TECH46m ago"Smart javelin" brings sensors and real-time data analysis to athleticsEuroNews [en]SCI & TECH1h agoUS: New York City Mayor Mamdani announces ban on AI for younger studentsDW News [en]SCI & TECH1h agoKFON set for network upgrade, tribal connectivity expansion in KeralamThe Hindu